This is the hover veil
Menu
Menu
Home
Living
guidelines
Clinical
flowcharts
Topics
under review
Do you have a clinical question?
About the taskforce
About the guidelines
FAQs
News
Contact us
About the taskforce
About the guidelines
FAQs
News
Contact us
News
News
Communique
Video
Explainer
Media release
Topics
Aboriginal and Torres Strait Islander people
ACEIs/ARBs
ACEM
ACIPC
ACNN
Acute & Critical Care
Adult disease-modifying treatment flowchart
Adults
AHPA
ALEC
Allied Health Professions Australia
Anakinra
Angiotensin 2 receptor agonist (C21)
Antenatal corticosteroids
Anticoagulants
Anticoagulation
Antivirals
ANZ Guidelines
ANZICS
ANZJOG
ANZPID COVID-19 Clinical Reference Group
Aprepitant
ARC
ASCOT
Asha Bowen
ASID
ATAGI
Australasian Sleep Association
Australia Day honours
Australian and New Zealand Society for Geriatric Medicine
Australian College of Midwives
Australian Commission on Safety and Quality in Health Care
Australian Living Evidence Consortium
Azithromycin
Baloxavir marboxil
Bamlanivimab
Bamlanivimab plus etesevimab
barac
Baricitinib
Basic Life Support
Bebtelovimab
BESSI principles
Breastfeeding
Brendan McMullan
Bridget Barber
Bromhexine hydrochloride
Budesonide
Budesonide for children and adolescents
Burnet
Camostat mesilate
Canakinumab
Cardiac arrest
Cardiac Arrest Working Group
Care of Children
Carol Hodgson
Casirivimab plus imdevimab
Casirivimab plus imdevimab (REGEN-COV)
Casirivimab plus imdevimab in children and adolescents
CD24c
CENA
Chemophrophylaxis
Chemoprophylaxis Panel
CHF
Children & adolescents
Children and adolescents
Chloroquine
Ciclesonide
Clinical flowcharts
CMCS
Cochrane
Cochrane Convenes
Cochrane Reviews
Colchicine
COMET-ICE
Consumer Panel
Convalescent plasma
Corticosteroids
COVID-19 COS
CPAP/HFNO
CPR
CPR Flowcharts
Critical Disease Panel
Croup
CT-P59 monoclonal antibody
Darunavir-cobicistat
Decision aid
Decision Tool
Delayed umbilical cord clamping
Dexamethasone
Disease-modifying treatments
Disease-Modifying Treatments Panel
DMT flowchart for children and adolescents
DMTC Panel
Drug treatments
Dutasteride
ECMO
Enisamium
Evusheld
Expert Advisory Group
Extracorporeal membrane oxygenation
Eye protection
Face masks
Facebook
Favipiravir
Flowchart
GIN
Global Commission on Evidence
GPs
Guideline Leadership Group
Guidelines Leadership Group
HCW
High-flow nasal oxygen
Hospital and Acute Care Panel
Hydroxchloroquine
Hydroxychloroquine
Hydroxychloroquine plus azithromycin
Ian Potter Foundation
ICEG
Imatinib
Immunodulatory treatments table
Immunoglobulin
Immunoglobulin plus methylprednisolone
Immunosuppressed
Infection Control Matters Podcast
Infection Prevention and Control (IPC) Panel
Infectious Disease
Inhaled corticosteroids
Interferon beta-1a
Interferon Gamma
Interferon β-1a (inhaled)
International Women's Day
Intravenous immunoglobulin
IPC
IPC Panel
Ivermectin
Josh Davis
Kawasaki Disease
Lancet
Leadership
Lenzilumab
Living Evidence
Long COVID
Lopinavir-ritonavir
Magnesium Sulfate
Management of cardiac arrest
Mild COVID-19
MJA
Molnupiravir
Molnupiravir (Lagverio)
Monoclonal antibody therapy
Murray PHN
N-acetylcysteine
NCIRS
Neonatal
Neonates
New England Journal of Medicine
New Topics & Questions
NHMRC
NICE
Nirmatrelvir plus ritonavir (Paxlovid)
Non-invasive ventilation
NPS MedicineWise
Observational Data Working Group
Oestrogen containing therapies
Oral antivirals
P2/N95 respirators
Paediatric
Paediatric & Adolescent Care
Paediatric & Adolescent Care Panel
Paediatric Care
Palliative and Aged Care Panel
Palliative Care
Palliative Care Working Group
Pathways to Care
Peginterferon lambda
Personal Protective Equipment (PPE)
PIMS-TS
Podcast
Post-acute COVID-19
Post-acute flowchart
post-exposure prophylaxis
Post-viral symptoms
Postnatal
PPE
pre-exposure prophylaxis
Pregnancy and breastfeeding women
Pregnancy and perinatal care
Pregnancy and Perinatal Panel
Pregnancy disease-modifying treatments flowchart
Pregnant & Breastfeeding Women
Pregnant & Postpartum women
Pregnant or breastfeeding women
Pregnant women
Primary and Chronic Care Panel
Prone positioning
Prone positioning for adults (non-ventilated)
Proxalutimide
Pulse oximeters
RANZCOG
RCTs
RECOVERY Trial
Regeneron
REGN-COV2
REMAP-CAP
Remdesivir
Respiratory
Respiratory management
Respiratory support
Risk classification tool
RMSANZ
Ronapreve
Royal Australian College of Surgeons
Ruxolitinib
Sarilumab
Senior Clinical Fellow
severe-critical COVID-19
SMS notifications
Sofosbuvir plus daclatasvir
Sotrovimab
Special populations
Steering Committee
Steroids
Steve McGloughlin
subcutaneous casirivimab plus imdevimab
Subscription
TaskforceTV
Telmisartan
TGA
THANZ
The Alfred
The Conversation
Thromboembolism
Timing of surgery
Tixagevimab plus cilgavimab (Evusheld)
Tocilizumab
Tociluzimab
Tofacitinib
Tracheostomy
Treatment
TSANZ
Umifenovir
Unvaccinated
Vaccination
Venous thromboembolism (VTE) prophylaxis
Videolaryngoscopy
Vitamin C
Vitamin D
VTE prophylaxis
Webinar
Zinc
Featured
COVID-19 Research Pipeline
STUDIES
Cochrane COVID-19 Study Register
137,915
Registered/ Published
RCT
s
covid-nma.com
4,281
Registered
658
Published
SYSTEMATIC REVIEWS
Prospero
6,015
Registered
As at 27 May 2022
Tweets by evidenceCOVID19
FILTERED BY > Cochrane
Clear filter
Communique #51
15 October, 2021
WEEK IN REVIEW Updates to the Living Treatment Guidelines New recommendations New recommendation for Continuous positive airway pressure / High-flow nasal oxygen therapy The Hospital and Acute Care Panel have incorporated the results of the recent RECOVERY-Respiratory Support trial (Perkins et al.) into the evidence base for respiratory support. The previous recommendation for High flow nasal oxygen therapy (HFNO) was based on indirect evidence but...
Communique
Communique #49
26 August, 2021
WEEK IN REVIEW Taskforce makes new conditional recommendation for sotrovimab The Taskforce today published three recommendations on the use of sotrovimab for the treatment of COVID-19 in adults...
Communique
Coverage: Understanding evidence
17 August, 2021
Science reporter for the The Age and Sydney Morning Herald, Liam Mannix explains the critical role of gold standard evidence and highlights the role of Cochrane and the...
News
Communique #45
3 June, 2021
Dear colleagues, On behalf of our 32 Taskforce members, we acknowledge our Victorian colleagues during another challenging and anxious time. Look after yourselves and each other, and we all hope an easing of...
Communique
Communique #42
22 April, 2021
Message from the Chair and Executive Director Dear Colleagues We’ve just passed 12-months since the first publication of the Australian clinical guidelines for the care of people with COVID-19....
Communique
Communique #41
1 April, 2021
WEEK IN REVIEW UPDATES TO THE LIVING GUIDELINE Convalescent plasma recommendation changed to 'do not use' The Taskforce Disease Modifying and Chemoprophylaxis Panel and the Guidelines Leadership Group have incorporated...
Communique
Communique #40
18 March, 2021
WEEK IN REVIEW UPDATES TO THE LIVING GUIDELINE New recommendation for tocilizumab in children or adolescents Further to the Taskforce's recent recommendation for the conditional use of tocilizumab for adults (25...
Communique
Communique #39
25 February, 2021
WEEK IN REVIEW UPDATES TO THE LIVING GUIDELINE Tocilizumab upgraded to conditional recommendation The Taskforce Disease Modifying Treatment and Chemoprophylaxis Panel and the Guidelines Leadership Group have incorporated...
Communique
Communique #38
11 February, 2021
Message from the Taskforce Chair Dear colleagues As we enter the second year of the COVID-19 pandemic it is timely to acknowledge the important role of the Taskforce’s...
Communique
Communique #37
29 January, 2021
Following a well-earned break, the Taskforce team has now returned to full capacity. Global evidence surveillance continued throughout January, with six clinical panel meetings held since January 11....
Communique
Weekly Communique #36
17 December, 2020
Dear colleagues, It’s hard to fully comprehend a year like 2020. The pandemic has affected us all and no doubt its impact will continue and reverberate for some...
Communique
Weekly Communique #35
10 December, 2020
WEEK IN REVIEW Updates to the living guideline New recommendations published this week cover: Combined metabolic cofactor supplementation (CMCS) Vitamin D analogues (formerly just calcifediol, now also includes cholecalciferol) Updated...
Communique
Weekly Communique #33
26 November, 2020
WEEK IN REVIEW Updates to the living guideline Three new recommendations have been published this week covering: Bamlanivimab Fluvoxamine Intravenous immunoglobulin VTE prophylaxis for children and adolescents Further details are...
Communique
Weekly Communique #31
12 November, 2020
WEEK IN REVIEW IPC Panel EOI for paediatric and clinical engineering expertise The Taskforce is calling for Expressions of Interest from suitably qualified individuals with paediatric or clinical...
Communique
Weekly Communique #30
5 November, 2020
WEEK IN REVIEW Bromhexine hydrochloride added to list of 'only in clinical trials' The Disease-Modifying Treatment and Chemoprophylaxis Panel has reviewed two new trial results for bromhexine hydrochloride (commonly...
Communique
Weekly Communique #29
29 October, 2020
WEEK IN REVIEW Updates to the living guideline this week New recommendations Three new recommendations have been published covering: Triazavirin Other immunomodulatory agents (PIMS-TS) Aspirin and antithrombotic agents...
Communique
Weekly Communique #28
22 October, 2020
WEEK IN REVIEW SAVING LIVES SAFELY: New CPR flowcharts published today The Taskforce, in partnership with the Infection Control Expert Group (ICEG), has published new clinical flowcharts to guide clinicians...
Communique
Weekly Communique #27
15 October, 2020
WEEK IN REVIEW New PIMS-TS recommendations The Taskforce has made two new consensus recommendations for the management of children with suspected or confirmed Paediatric Inflammatory Multisystem Syndrome Temporally associated with SARS-CoV-2...
Communique
Weekly Communique #26
8 October, 2020
With our evidence team and panels taking a much-needed break, a smaller edition today with no new recommendations or updates to the guidelines and flowcharts this week. Our next update will be next Thursday,...
Communique
Weekly Communique #12
2 July, 2020
WEEK IN REVIEW Taskforce makes first recommendation on Dexamethasone The Taskforce has made two conditional recommendations on the use of dexamethasone in treatment of patients with COVID-19: Consider...
Communique
Weekly Communique #7
28 May, 2020
WEEK IN REVIEW The Taskforce has issued a consensus recommendation to consider increased-dose venous thromboembolism (VTE) prophylaxis for adults with severe to critical COVID-19. This recommendation was developed with input from thrombosis specialists on the Taskforce's...
Communique